Evidence map›Paper›PMID 41829281›Full record

ArticlePolymers2026

Tailoring Impact Toughness of PA6: Isolated Effects of Modifier Octene Content and Molecular Weight in MAH-Grafted EOR Copolymers.

Abdul Kadir Deeb, Oliver Neuß, Silke Rathgeber

Abstract read
In one paragraph

Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abdul Kadir DeebInstitute for Integrated Natural Sciences, Physics Department, University of Koblenz, Universitätsstraße 1, 56070 Koblenz, Germany.
Oliver NeußAKRO-PLASTIC GmbH, Im Stiefelfeld 1, 56651 Niederzissen, Germany.
Silke RathgeberInstitute for Integrated Natural Sciences, Physics Department, University of Koblenz, Universitätsstraße 1, 56070 Koblenz, Germany.

Funding

AKRO-PLASTIC GmbH
6 · The paper itself

Abstract

The impact modification of polyamide 6 (PA6) using maleic anhydride grafted ethylene/1-octene copolymers (EOR-g-MAH) is well-established, yet the isolated influence of intrinsic modifier parameters-specifically octene content coct and molecular weight MW-remains insufficiently understood due to confounding microstructural effects. This study presents a systematic approach to decouple these variables by maintaining constant grafting degree, modifier content, and compound morphology. A series of PA6/EOR-g-MAH compounds was prepared with controlled variations in coct (8-15 mol%) and MW (34-42 kg/mol). Instrumented Charpy impact testing across a temperature range from -40 °C to +23 °C enabled quantification of crack initiation and propagation energies (Einit and Eprop), providing mechanistic insight into the brittle-ductile transition. Complementary thermal, rheological, and tensile analyses of the modifiers revealed how coct governs cavitation behavior and low-temperature toughness, while MW in particular influences particle integrity and energy dissipation at elevated temperatures. The results demonstrate that targeted adjustment of coct and MW allows for the precise tuning of brittle-ductile transition temperature (BDTT) and impact resistance. The compound containing a high-MW modifier with intermediate coct (13 mol%) exhibited the most favorable balance of toughness and strength retention at elevated temperatures. These findings offer design principles for engineering thermoplastics with enhanced performance across broad service conditions.

Indexed as

ethylene/1-octene copolymersimpact strengthmaleic anhydridemolecular weightoctene content

Identifiers

PMID41829281
PMCPMC12986928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.